PTK2 and neoplasm: Former studies with this pharmacological inhibitor also demonstrated an effective reduction of ILK activity as well as a decrease of AKT (AKT kinase) and FAK (focal adhesion kinase) phosphorylation in tumor cell lines [36,38,44].